This company listing is no longer active
HG60 Stock Overview
A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mayne Pharma Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.50 |
| 52 Week High | AU$2.50 |
| 52 Week Low | AU$2.50 |
| Beta | 1.02 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| HG60 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -2.6% |
| 1Y | n/a | -15.6% | 6.9% |
Return vs Industry: Insufficient data to determine how HG60 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how HG60 performed against the German Market.
Price Volatility
| HG60 volatility | |
|---|---|
| HG60 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HG60 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HG60's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Shawn O’Brien | www.maynepharma.com |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.
Mayne Pharma Group Limited Fundamentals Summary
| HG60 fundamental statistics | |
|---|---|
| Market cap | €199.20m |
| Earnings (TTM) | -€171.79m |
| Revenue (TTM) | €277.11m |
0.7x
P/S Ratio-1.2x
P/E RatioIs HG60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HG60 income statement (TTM) | |
|---|---|
| Revenue | AU$424.80m |
| Cost of Revenue | AU$253.77m |
| Gross Profit | AU$171.03m |
| Other Expenses | AU$434.37m |
| Earnings | -AU$263.34m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Feb 23, 2023
| Earnings per share (EPS) | -3.07 |
| Gross Margin | 40.26% |
| Net Profit Margin | -61.99% |
| Debt/Equity Ratio | 72.8% |
How did HG60 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/25 23:28 |
| End of Day Share Price | 2023/01/19 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mayne Pharma Group Limited is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Russell Wright | APP Securities Pty Ltd. |
| Russell Wright | Barclay Pearce Capital Pty Limited |
| John Hester | Bell Potter |